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AbstrACt
Objectives Sex differences in respiratory physiology 
and predilection for developing chronic obstructive 
pulmonary disease (COPD) have been documented, 
suggesting that female sex hormones may influence 
pathogenesis. We investigated whether aspects of 
female reproductive health might play a role in risk of 
COPD among women.
Design Population-based prospective cohort study.
setting UK Biobank recruited across 22 centres in the UK 
between 2006 to 2010.
Primary and secondary outcomes measures We 
examined a range of female reproductive health indicators 
in relation to risk of COPD-related hospitalisation/death 
(n=271 271) using Cox proportional hazards regression; 
and lung function (n=273 441) using linear regression.
results Parity >3 was associated with greater risk 
of COPD-related hospitalisation/death (adjusted HR 
1.45; 95% CI: 1.16 to 1.82) and lower forced expiratory 
volume at 1 second/forced vital capacity ratio (FEV1/
FVC) (adjusted mean difference −0.06; 95% CI: -0.07 to 
0.04). Any oral contraception use was associated with 
lower risk of COPD-related hospitalisation/death (adjusted 
HR 0.85; 95% CI: 0.74 to 0.97) and greater FEV1/FVC 
(adjusted mean difference 0.01; 95% CI: 0.003 to 0.03). 
Late menarche (age >15) and early menopause (age 
<47) were also associated with greater risk of COPD-
related hospitalisation/death (but not lung function), while 
endometriosis was associated with greater FEV1/FVC (not 
COPD-related hospitalisation/death). Early menarche (age 
<12 years) was associated with lower FEV1/FVC (but not 
COPD hospitalisation/death). Associations with polycystic 
ovary syndrome (PCOS) or ovarian cysts, any hormone 
replacement therapy (HRT) use, hysterectomy-alone and 
both hysterectomy and bilateral oophorectomy were in 
opposing directions for COPD-related hospitalisation/death 
(greater risk) and FEV1/FVC (positive association).
Conclusions Multiple female reproductive health 
indicators across the life course are associated with 
COPD-related hospitalisation/death and lung function. 
Further studies are necessary to understand the 
opposing associations of PCOS/ovarian cysts, HRT and 
hysterectomy with COPD and objective measures of 
airway obstruction.
IntrODuCtIOn
There are clear sex differences in lung 
anatomy and physiology throughout the 
life course.1 This is also reflected in the risk 
of obstructive lung disease. For example, 
boys have greater risk of asthma during 
early childhood compared with girls, but 
this sex difference reverses after puberty, 
when girls are found to have the greater risk 
of new-onset asthma.2 Chronic obstructive 
pulmonary disease (COPD) has tradition-
ally been seen as a disease predominantly 
affecting men. However, in more recent 
years, the overall burden of the disease has 
shifted more towards women.2 3 Women with 
COPD also have, on average, fewer pack-years 
of smoking history than men with COPD; 
and non-smokers with COPD are more often 
strengths and limitations of this study
 ► This large, population-based, prospective cohort 
study is the first to assess chronic obstructive 
pulmonary disease (COPD) risk with age at men-
arche, menopause status, hysterectomy, gynaeco-
logical surgery, endometriosis or polycystic ovary 
syndrome.
 ► No study has examined a wide range of reproduc-
tive health indicators, spanning the reproductive and 
post-reproductive periods, with regards to COPD.
 ► We included a comprehensive list of potential con-
founders, such as age, height, body mass index, 
ethnicity, education, household income, Townsend 
deprivation index, smoking history, asthma, mater-
nal COPD and paternal COPD.
 ► We relied on participants to self-report reproductive 
history and we cannot exclude a potential influence 
of selection bias, due to the low participation rate in 
UK Biobank.
 ► Data on environmental tobacco smoke were not 
available and we cannot exclude residual bias from 
this exposure.
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Figure 1 Flow chart of study population. 
COPD denotes chronic obstructive pulmonary disease. 
Missing data is in one or more of the following variables: 
height, ethnicity, educational attainment, income, 
Townsend deprivation index, smoking history, spirometry 
measurements, maternal COPD history, paternal COPD 
history, age at menarche, menopause status, age at natural 
menopause, parity, oral contraception use, hormone 
replacement therapy use or gynaecological surgery history.
female.1 This points towards a greater underlying suscep-
tibility among women, and highlights the importance of 
understanding female-specific risk factors for COPD.
Female sex hormones are putative mediators of respi-
ratory health, and regulate bronchodilation, cell prolif-
eration, inflammation and metabolism of toxic cigarette 
smoke-related metabolites.1 4–7 Notably, oestrogen and 
progesterone appear to have varying effects on lung 
function across the lifespan.1 We know little, however, 
about female reproductive health indicators in relation 
to COPD risk.1 These reproductive health indicators 
include markers of endogenous hormone exposure (age 
at menarche, age at menopause and length of repro-
ductive lifespan), exogenous hormone exposure (oral 
contraceptive use and hormone replacement therapy), 
as well as pregnancy history. Of two existing studies, 
one study found no evidence of an association between 
hormone replacement therapy (HRT) and COPD risk,8 
while another reported a positive association between 
early age at first pregnancy (<20 years) and COPD-related 
mortality.9 There is more evidence regarding the relation-
ship between female reproductive health indicators and 
lung function. Early menarche,10–12 nulliparity,13 younger 
age at first pregnancy12 and postmenopausal status14–19 
have each been associated with reduced lung function. 
Evidence of the effects of HRT is contradictory.14 15 20 21 In 
the present study, we therefore investigate associations of 
multiple female reproductive health indicators across the 
lifespan with incidence of COPD hospitalisation/death 
and lung function in the UK Biobank cohort.
MethODs
study population
Our study included female participants in UK Biobank 
(figure 1), a population-based cohort study which 
recruited men and women age 40 to 69 years across 22 
centres in England, Wales and Scotland between 2006 
to 2010.22 The response rate was 5.5%.22 All participants 
provided written informed consent. Data on 273 441 
women were available after withdrawals. At baseline, 
participants self-reported sociodemographic informa-
tion, family medical history, early-life exposures, psycho-
social history and medical history. Physical measurements 
included spirometry. Information on health outcomes 
after recruitment into the cohort was gathered prospec-
tively via data linkages with hospital and death registers. 
Register data were available up to 28 February 2015 for 
England, 16 March 2015 for Wales and 28 October 2014 
for Scotland. UK Biobank does not require separate 
ethics approvals for specific analyses. A generic Research 
Tissue Bank approval for access to UK Biobank data 
and/or samples has been recommended by the National 
Research Ethics Service and has been obtained from 
the governing UK Biobank Research Ethics Committee 
(http://www. ukbiobank. ac. uk/ wp- content/ uploads/ 
2012/ 09/ Access- Procedures- 2011- 1. pdf). Applications 
to access the resource are approved by the UK Biobank 
Access Sub-Committee and Ethics & Governance Council.
Female reproductive health indicators
We investigated the following self-reported female repro-
ductive health indicators: age at menarche (<12, 12 to 15 
and >15 years), menopause status (no, yes), age at natural 
menopause (<47, 47 to 49, 50 to 52 and >52 years), parity 
(0, 1, 2, 3 and >3), history of polycystic ovary syndrome 
(PCOS) or ovarian cysts, history of endometriosis, oral 
contraception (OC) use (never/ever), years of OC use 
(0, 1, 2 to 4, 5 to 9, 10 to 15 and >15), hormone replace-
ment therapy (HRT) use (never/ever), years of HRT use 
(0, 1 to 2, 3 to 5, 6 to 10 and >10) and gynaecological 
surgery (hysterectomy, oophorectomy and hysterectomy 
with bilateral oophorectomy). We calculated years of OC 
and HRT use as the differences between age at first and 
last use, and created categories according to quintiles.
Amaral et al previously reported decreased lung func-
tion in postmenopausal women in UK Biobank.16 We 
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repeat these analyses for completeness alongside analyses 
of other female reproductive health indicators.
respiratory outcomes
Prevalent COPD at baseline was identified using self-re-
port and registrations before baseline in the hospital 
registers. Incident hospitalisations/deaths from COPD 
after baseline were identified using hospital and death 
registers. The following International Classification of 
Diseases (ICD) codes were used to capture COPD: ICD-9 
codes 490 to 492, 494 and 496, or ICD-10 codes J40 to J44.
Forced expiratory volume at 1 second (FEV1) and 
forced vital capacity (FVC) were measured using Vitalo-
graph Pneumotrac 6800 (Vitalograph, UK) at baseline. 
Spirometry was not performed if participants had experi-
enced a chest infection in the last month; had a lifetime 
history of detached retina or collapsed lung; had experi-
enced a heart attack, eye surgery or surgery to the chest or 
abdomen in the last 3 months; were currently pregnant in 
the first or third trimester or were currently using medica-
tion for tuberculosis. Two measurements were conducted 
if the difference between these measurements was ≤5%. 
A third measurement was conducted if the difference was 
>5%. We used the single greatest measurements of FEV1 
and FVC per participant. Post-bronchodilator spirometry 
was not available, although drug treatment was not with-
held. Spirometry measurements were converted to inter-
nally standardised z-scores by age and height based on 
the Global Lung Initiative 2012 recommendations23 to 
reduce bias related to age. These z-scores were used for 
all analyses.
statistical analyses
We used Cox proportional hazards regression to examine 
the association of each female reproductive health indi-
cator in relation to incidence of COPD hospitalisation/
death. Participants without COPD at baseline were 
followed from enrolment until hospitalisation/death 
from COPD, death from other causes or the end of 
follow-up if the participants were still alive and disease-
free. The time axis for the Cox regression was calendar 
time. We examined deviations from the proportional 
hazard assumption using Schoenfeld residuals.24 Age-ad-
justed and confounder-adjusted estimates are reported 
as HR with 95% CI. The following potential confounders 
were included in multivariable analyses: age, height, 
log-transformed body mass index (BMI) at baseline, 
ethnicity (White or non-White), educational attain-
ment (college, university or other professional degree; 
Advanced levels, Advanced Subsidiary levels or equiva-
lent; Ordinary levels, General Certificate of Secondary 
Educations or equivalent; Certificate of Secondary Educa-
tions or equivalent; National Vocational Qualifications, 
Higher National Diploma, Higher National Certificate or 
equivalent; other), annual household income (<£18 000, 
£18 001 to £31 000, £31 001 to £52 000, £52 001 to £100 
000, >£100 000), Townsend deprivation index, smoking 
history in pack-years (none, <11, 11 to 20, 21 to 30, >30), 
and parental history of COPD. We performed sensitivity 
analyses of (1) menopause status and age at natural meno-
pause with further adjustment for HRT; (2) menopause 
status excluding participants age <45 years or >60 years at 
baseline to reduce potential bias by age; (3) all reproduc-
tive health indicators after excluding participants with 
respiratory conditions (ie, COPD, asthma, tuberculosis 
or pneumonia) reported at baseline or FEV1/FVC<0.7 at 
baseline, as they possibly had undiagnosed COPD25; (4) 
all reproductive health indicators with smoking history 
adjusted as two covariates (duration in years and average 
number of cigarettes/day) rather than one covariate 
(pack-years); (5) all reproductive health indicators with 
further adjustment for baseline smoking status (never, 
previous, current); (6) all reproductive health indicators 
after excluding participants with any history of smoking 
and (7) all reproductive health indicators with further 
adjustment for other comorbidities (cardiovascular 
disease or diabetes) reported at baseline.
We used linear regression in the analysis of stan-
dardised spirometry measurements. The multivariable 
linear regression models were adjusted for the same 
covariates as for hospitalisation/death from COPD, with 
the addition of asthma at baseline. We reported results as 
mean difference in the spirometry measurements z-scores 
with 95% CI. These mean differences in z-scores can be 
converted to raw values by multiplication with the SD in 
spirometry measurement for the given age and height 
group. Sensitivity analyses for standardised spirometry 
measurements were also conducted with: (1) menopause 
status excluding participants age <45 years or >60 years 
at baseline, (2) smoking history adjusted as two covari-
ates (duration in years and average number of cigarettes/
day), (3) further adjustment for baseline smoking status 
and (4) further adjustment for comorbidities baseline 
(cardiovascular disease or diabetes).
We performed multiple imputation by chained equa-
tions to account for missing data. Exposures, covariates 
and outcomes were included in the imputation model. 
We imputed 20 data sets, which were then analysed using 
Rubin’s rules.26 Details of the imputation model are given 
in the online supplementary file table S1. All analyses were 
performed using Stata/MP 15 (StataCorp LLC, College 
Station, USA). Sensitivity analyses of the complete cases 
was performed for comparison with our imputed data.
Patient and public involvement
The present study did not involve patients and the public.
results
Of the 273 441 women included in this study, 2170 had 
prevalent COPD at baseline (figure 1). These preva-
lent cases were excluded from the analysis of incident 
COPD-related hospitalisation/death. By the end of 
follow-up (median 6 years), there were 1138 incident 
cases of hospitalisation/death from COPD, yielding an 
incidence rate of 0.19 per 100 000 person years.
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In UK Biobank, 28.4% of women did not have spirom-
etry data, 16.1% were uncertain of or did not report 
menopause status and 14.3% did not report smoking 
history. The proportion of missing information on the 
other covariates were modest (table 1). Overall, women 
with spirometry data were younger, more often White, 
had higher educational attainment, higher annual house-
hold income, less deprivation (lower Townsend index), 
greater smoking history and were more likely to have 
asthma than women who did not undergo spirometry 
assessment (online supplementary file table S2). The 
distribution of participants’ characteristics across the 
imputed data sets is shown in table 1.
Late (age >15 years) menarche was associated with 
increased risk of hospitalisation/death from COPD 
compared with menarche between age 12 to 15. The 
multiple-adjusted HR was 1.37 (95% CI: 1.11 to 1.71) 
(table 2). There was a modest association between early 
menarche and COPD hospitalisation/death (HR 1.15; 
95% CI: 1.00 to 1.32). Early menarche (age <12 years) 
was associated with lower FEV1/FVC (table 3).
Risk of hospitalisation/death from COPD did not differ 
between premenopausal and postmenopausal women 
(table 2), and this finding was similar after further 
adjusting for HRT use (HR 1.02; 95% CI: 0.78 to 1.35). 
In examining age at menopause and risk hospitalisa-
tion/death from COPD among women who experienced 
natural menopause (n=159 571), the risk was higher in 
women who experienced menopause age <47 years (HR 
1.44; 95% CI: 1.19 to 1.75) when compared with age 50 
to 52 (table 2). This association remained after further 
adjustment for HRT use (HR 1.43; 95% CI: 1.18 to 1.74). 
Postmenopausal status at baseline and early natural 
menopause were each associated with lower FEV1 and 
FVC but not FEV1/FVC (table 3). These associations did 
not change after further adjustment for HRT ever use 
(results not shown). After restricting the sample to partic-
ipants who were age 45 to 60 years (inclusive) at the time 
of reporting menopause status to reduce residual bias 
due to age, we found that menopause status was positively 
associated with COPD-related hospitalisation/death 
(HR 1.57; 95% CI: 1.07 to 2.30), while associations with 
spirometry measures did not change (results not shown).
Hospitalisation/death from COPD did not differ 
between parous and nulliparous women, but parity >3 
was associated with increased risk (HR 1.45; 95% CI: 1.16 
to 1.82) compared with nulliparity. Women who were 
nulliparous had lower FEV1 and FVC but greater FEV1/
FVC compared with parous women, while women with 
parity >3 had greater FEV1 and FVC but lower FEV1/FVC 
compared with nulliparous women (table 3).
A history of PCOS or ovarian cysts was associated with 
increased risk of hospitalisation/death from COPD (HR 
1.61; 95% CI: 1.12 to 2.32) and greater FEV1/FVC (mean 
difference 0.05; 95% CI: 0.02 to 0.09), while there was no 
evidence of an association with FEV1 or FVC. A history 
of endometriosis was not associated with COPD hospital-
isation/death, FEV1 or FVC (tables 2 and 3), though we 
observed a modest positive association with FEV1/FVC 
(mean difference 0.07; 95% CI: 0.03 to 0.10).
We observed several associations between exogenous 
hormone use and COPD hospitalisation/death. Women 
who had ever used OC had lower risk of hospitalisation/
death from COPD compared with never users (HR 0.85; 
95% CI: 0.74 to 0.97) (table 2). This appeared to be 
driven by OC use of >9 years (table 2). In line with the 
observed findings for COPD, OC ever use and duration 
of use showed positive associations with FEV1, FVC and 
FEV1/FVC (table 3).
Ever using HRT was associated with a modest increased 
risk of hospitalisation/death from COPD (HR 1.15; 95% 
CI: 1.01 to 1.30) (table 2). We observed no associations 
of HRT ever use with FEV1 or FVC, but a positive associ-
ation with FEV1/FVC (table 3). When we examined the 
duration of HRT use, we only observed increased hospi-
talisation/death from COPD (HR 1.33; 95% CI: 1.12 to 
1.57) and greater FEV1/FVC (mean difference 0.02; 95% 
CI: 0.01 to 0.04) with 1 to 2 years of use (tables 2 and 3). 
There was no evidence of a dose-response relationship.
A history of hysterectomy (with or without bilateral 
oophorectomy), but not bilateral oophorectomy-alone, 
were associated with greater risk of COPD hospitalisa-
tion/death (table 2). At the same time, hysterectomy 
was associated with higher, rather than lower, FEV1/FVC 
(table 3). Hysterectomy with bilateral oophorectomy was 
also associated with lower FVC (table 3).
The directions of association between individual female 
reproductive health indicators with COPD risk and 
spirometry measures are summarised in table 4. Either 
a respiratory illness (asthma, COPD, tuberculosis and/
or pneumonia) and/or FEV1/FVC<0.7 at baseline was 
reported by 55 929 women. However, our findings after 
excluding these women from our analyses of COPD-re-
lated hospitalisation/death were similar to our main find-
ings (online supplementary file table S3).
We report the results of our sensitivity analyses, after 
(1) further adjusting for baseline smoking status; (2) 
adjusting for smoking history as two covariates including 
duration in years of smoking and average number of 
cigarettes per day; (3) excluding women who have 
ever smoked or (4) further adjusting for cardiovascular 
disease or diabetes reported at baseline, in the online 
supplementary file tables S4-S8. The direction and magni-
tude of associations remained similar for risk of COPD 
hospitalisation/death (online supplementary file tables 
S4 and S6) and change in spirometry measures (online 
supplementary file tables S7 and S8) after further adjust-
ment for the above covariates. In our analyses of never 
smokers (n=161 626), however, associations of COPD-re-
lated hospitalisation/death with early menopause, parity 
>3, PCOS/ovarian cysts, ever using oral contraception 
or hormone replacement therapy became null (online 
supplementary file table S5). Early age at menarche 
(<12 years) was also positively associated with COPD-re-
lated hospitalisation/death in this restricted sample of 
never smokers (HR 1.39; 95% CI: 1.02 to 1.90), while the 
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Table 1 Distribution of observed and imputed data in UK biobank women at baseline (n=273 441)
Characteristic % data imputed Mean (SE) or % in observed data Mean (SE) or % in imputed data
Age (years) 0 56.35 (0.02) 56.35 (0.02)
  <55 39.5 39.5
  55–59 18.6 18.6
  60–64 24.2 24.2
  >64 17.8 17.8
Height (cm) 0.4 162.4 (0.01) 162.4 (0.01)
Body mass index (kg/m2) 0
  <18.5 0.8 0.8
  18.5–24.9 38.7 38.7
  25.0–29.9 36.5 36.5
  >29.9 24.1 24.1
Non-white ethnicity 0.5 5.4 5.4
Education 1.2
  College, university or other professional degree 36.9 37.3
  A levels, AS levels or equivalent 11.8 11.9
  O levels, GCSEs or equivalent 23.3 23.5
  CSE or equivalent 5.4 5.4
  NVQ, HND, HNC or equivalent 4.5 4.6
  Other 17.0 17.3
Annual household income 0.4
  <£18 000 20.4 20.6
  £18,000-£30 999 21.7 21.8
  £31,000-£51 999 20.9 21.0
  £52,000-£100 000 15.3 15.4
  >£100 000 4.0 4.0
  Do not know/prefer not to answer 17.3 17.4
Townsend deprivation index 0.1 −1.33 (0.01) −1.33 (0.01)
Smoking history (pack-years) 14.3
  None 59.3 69.1
  Up to 10 7.9 9.2
  11-20 7.4 8.7
  21–30 5.2 6.1
  >30 5.9 6.9
Prevalent (baseline) COPD 0 0.8 0.8
Incident COPD hospitalisation/death 0 0.4 0.4
Spirometry* 28.4
  FEV1 z-score 0.00001 (0.002) −0.0008 (0.002)
  FVC z-score −0.000002 (0.002) −0.001 (0.002)
  FEV1/FVC z-score 0.00003 (0.002) 0.002 (0.002)
Asthma 0 12.9 12.9
Maternal history of COPD 1.9
  No 90.0 91.7
  Yes 6.0 6.1
  Don’t know 2.2 2.2
Paternal history of COPD 3.0
  No 81.7 84.2
  Yes 10.3 10.6
  Don’t know 5.0 5.2
Continued
by copyright.
 o
n
 N
ovem
ber 22, 2019 at University of Bristol Library. Protected
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-030318 on 28 October 2019. Downloaded from 
6 Tang R, et al. BMJ Open 2019;9:e030318. doi:10.1136/bmjopen-2019-030318
Open access 
Characteristic % data imputed Mean (SE) or % in observed data Mean (SE) or % in imputed data
Age at menarche, years 3.3
  <12 19.4 20.0
  12-15 71.7 74.1
  >15 5.7 5.9
Menopause status 16.1
  No 23.4 26.4
  Yes 60.5 73.6
Age at natural menopause, years 20.8
  <47 11.4 20.7
  47–49 8.9 12.8
  50–52 19.7 23.7
  >52 15.8 16.3
  Did not undergo natural menopause 23.4 26.4
Parity 1.9
  Nulliparous 14.7 15.0
  Parous 83.4 85.0
  1 11.9 12.2
  2 33.7 34.4
  3 24.8 25.3
  >3 12.9 13.2
PCOS/ovarian cysts 0 1.7 1.7
Endometriosis 0 1.5 1.5
Oral contraception use, years 0.5
  Never 18.9 19.0
  Ever 80.6 81.0
  1 11.0 11.1
  2-4 18.6 18.7
  5-9 17.7 17.7
  10-15 17.4 17.4
  >15 16.0 16.0
Hormone replacement therapy, years 5.7
  Never 61.4 63.7
  Ever 32.9 36.3
  1-2 10.7 11.8
  3-5 8.4 9.1
  6-10 5.7 6.2
  >10 8.2 9.2
Gynaecological surgery 1.8
  No 80.4 81.7
  Hysterectomy 9.9 10.1
  Bilateral oophorectomy 0.4 0.4
  Both 7.6 7.8
*Spirometry measures were standardised by age, sex and height.
A levels, advanced levels; AS levels, advanced subsidiary levels; COPD, chronic obstructive pulmonary disease; CSE, certificate of secondary education; 
FEV1, forced expiratory volume at 1 second; FVC, forced vital capacity; GCSE, General Certificate of Secondary Educations; HNC, higher national certificate; 
HND, higher national diploma; NVQ, national vocational qualifications; O levels, ordinary levels; PCOS, polycystic ovary syndrome; SE, standard error.
Table 1 Continued
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Table 2 Cox regression analyses of female reproductive health indicators with incident COPD-related hospitalisation/death 
during follow-up in women without COPD at baseline (n=271 271)
Reproductive health 
indicator
% of 
participants
Person-years of 
follow-up
Number of 
COPD events
Age-adjusted Multiple-adjusted*
HR 95% CI HR 95% CI
Age at menarche
  <12 years 20.0 326 027 275 1.31 1.14 to 1.51 1.15 1.00 to 1.32
  12–15 years 74.1 1 210 146 768 1.0 NA 1.0 NA
  >15 years 5.9 95 771 95 1.61 1.29 to 1.99 1.37 1.11 to 1.71
Menopause status
  No 26.6 437 890 97 1.0 NA 1.0 NA
  Yes 73.4 1 194 055 1041 1.47 1.12 to 1.94 1.07 0.82 to 1.41
Age at natural menopause†
  <47 years 20.3 202 811 270 2.21 1.83 to 2.68 1.44 1.19 to 1.75
  47–49 years 15.8 158 718 140 1.55 1.24 to 1.94 1.25 1.00 to 1.57
  50–52 years 35.4 354 774 219 1.0 NA 1.0 NA
  >52 years 28.4 283 721 161 0.86 0.69 to 1.06 0.93 0.75 to 1.15
Parity, binary
  Nulliparous 15.1 244 938 116 0.77 0.63 to 0.93 0.92 0.76 to 1.12
  Parous 84.9 1 387 009 1022 1.0 NA 1.0 NA
Parity, ordered categories
  0 15.1 244 938 116 1.0 NA 1.0 NA
  1 12.2 198 124 139 1.41 1.10 to 1.81 1.06 0.82 to 1.35
  2 34.4 562 339 308 0.96 0.78 to 1.19 0.92 0.74 to 1.14
  3 25.3 413 347 293 1.24 1.00 to 1.54 1.06 0.85 to 1.33
  >3 13.1 213 195 282 2.21 1.78 to 2.75 1.45 1.16 to 1.82
PCOS/ovarian cysts
  No 98.3 1 604 641 1108 1.0 NA 1.0 NA
  Yes 1.7 27 304 30 1.61 1.12 to 2.32 1.61 1.12 to 2.32
Endometriosis
  No 98.5 1 607 817 1127 1.0 NA 1.0 NA
  Yes 1.5 24 131 11 0.79 0.44 to 1.43 0.85 0.47 to 1.53
Oral contraception
  Never used 18.9 308 641 295 1.0 NA 1.0 NA
  Ever used 81.1 1 323 303 843 0.95 0.83 to 1.09 0.85 0.74 to 0.97
Years of oral contraception use
  0 18.9 308 641 295 1.0 NA 1.0 NA
  1 11.1 180 195 137 1.05 0.85 to 1.29 0.84 0.69 to 1.04
  2–4 18.7 306 053 246 1.05 0.88 to 1.24 0.95 0.80 to 1.13
  5–9 17.8 290 554 181 0.92 0.76 to 1.11 0.86 0.71 to 1.05
  10–15 17.5 285 766 153 0.84 0.69 to 1.03 0.74 0.61 to 0.91
  >15 16.1 260 734 126 0.83 0.67 to 1.04 0.75 0.60 to 0.93
HRT
  Never used 63.9 1 042 083 510 1.0 NA 1.0 NA
  Ever used 36.1 589 861 628 1.49 1.31 to 1.69 1.15 1.01 to 1.30
Years of HRT
  0 63.9 1 042 083 510 1.0 NA 1.0 NA
  1–2 11.7 190 902 240 1.83 1.54 to 2.16 1.33 1.12 to 1.57
  3–5 9.1 147 962 162 1.63 1.34 to 1.97 1.17 0.97 to 1.42
  6–10 6.2 100 921 74 1.0 0.77 to 1.31 0.87 0.66 to 1.14
Continued
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Reproductive health 
indicator
% of 
participants
Person-years of 
follow-up
Number of 
COPD events
Age-adjusted Multiple-adjusted*
HR 95% CI HR 95% CI
  >10 9.2 150 077 152 1.27 1.04 to 1.55 1.06 0.87 to 1.29
Gynaecological surgery
  No 81.8 1 335 512 765 1.0 NA 1.0 NA
  Hysterectomy 10.1 164 869 213 1.77 1.51 to 2.07 1.49 1.28 to 1.74
  Bilateral oophorectomy 0.4 5957 6 1.56 0.70 to 3.48 1.36 0.61 to 3.04
  Both 7.8 125 607 154 1.68 1.41 to 2.00 1.42 1.19 to 1.69
*Multiple-adjusted for age, height, body mass index (log-transformed), ethnicity, education, household income, Townsend deprivation index, smoking 
history, maternal COPD and paternal COPD.
†Age at menopause was analysed only among women who experienced natural menopause before baseline (n=159 571).
COPD, chronic obstructive pulmonary disease; HRT, hormone replacement therapy; PCOS, polycystic ovary syndrome.
Table 2 Continued
remaining associations were unchanged from the main 
analyses.
We also investigated associations of reproductive health 
indicators with risk of COPD-related mortality, and not 
hospitalisation, among women of UK Biobank. The asso-
ciations from these analyses of 273 441 women (including 
those with COPD reported at baseline) were null for all 
reproductive health indicators (online supplementary file 
table S9), except age at menarche <12 years compared 
with 12 to 15 years (HR 1.52; 95% CI: 1.08 to 2.13). 
However, there were only 179 COPD-related deaths in UK 
Biobank and many categories of our reproductive health 
indicators experienced fewer than 10 events. Complete-
case analyses of the risk of COPD hospitalisation/death 
(online supplementary file Table S10) and lung func-
tion (online supplementary file table 11) also produced 
similar results to those from our imputed data set.
DIsCussIOn
In this large, prospective study, several female reproduc-
tive health indicators were associated with COPD hospi-
talisation/death and/or lung function. Parity greater 
than three was associated with decreased baseline FEV1/
FVC, a marker of airway obstruction, and increased risk 
of hospitalisation/death from COPD during follow-up. 
Ever using OC was associated with greater FEV1/FVC 
and lower risk of COPD hospitalisation/death. Associa-
tions of hysterectomy, HRT use and a history of PCOS or 
ovarian cysts showed inconsistent findings for FEV1/FVC 
and COPD hospitalisation/death. This inconsistency may 
be explained by the fact that spirometry was measured in 
participants at baseline (age 40 to 69) and FEV1 and FEV1/
FVC may have declined during follow-up. Conversely, 
many patients diagnosed with stage 1 COPD do not go 
on to develop COPD symptoms or COPD resulting in 
hospitalisation/death.27 There is also high intra-indi-
vidual variability in FEV1.
28 Spirometry assessment at one 
time point may therefore not be as accurate at identifying 
clinically-relevant COPD compared with register data on 
hospitalisation/death.
A study of 424 797 postmenopausal women in the 
United States reported no difference in COPD mortality 
by parity.9 In contrast, our present study reports higher 
risk of COPD hospitalisation/death among women 
with more than three births compared with nulliparous 
women. However, we investigated both COPD-related 
hospitalisation and death, and we were therefore able to 
capture less severe COPD cases. A study of 70 965 women 
in the Nurses’ Health Study reported no evidence of an 
association between HRT ever use and COPD incidence, 
although the investigators included both probable 
(self-reported physician diagnosis along with a record of 
spirometry or imaging at the time of diagnosis or COPD 
documented on a death register) and definite (self-re-
ported physician diagnosis and FEV1 <80% predicted) 
cases of COPD.8 Here we report a positive association 
between HRT use and COPD hospitalisation/death. This 
is the first study to assess COPD risk with regards to age at 
menarche, menopause status, hysterectomy, gynaecolog-
ical surgery, endometriosis or PCOS.
Two previous studies reported reduced FEV1 in adult 
women who experienced menarche before age 1010 12 but 
neither found evidence of an association between age at 
menarche and FEV1/FVC. A Mendelian randomisation 
study of adolescent and adult women across multiple 
European cohorts, including a subset from UK Biobank, 
estimated a 24.8 mL increase in FVC per year increase 
in age at menarche among adult women and a −56.6 mL 
decrease in FVC per year increase in age at menarche 
among adolescent girls.11 This study reported no associa-
tion between age at menarche and FEV1/FVC.
11 Notably, 
this Mendelian randomisation study did not explore 
non-linear associations between age at menarche and 
measures of lung function. We observed lower FEV1 and 
FVC in adult women with late menarche, and lower FVC 
and FEV1/FVC in adult women with early menarche.
A recent systematic review, which included studies from 
UK Biobank,16 reported that postmenopausal status was 
associated with reduced FEV1 and FVC but not FEV1/
FVC.18 Current HRT use has been associated with both 
higher14 and lower15 lung function. One study reported 
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Table 4 Direction of association for female reproductive health indicators with risk of COPD-related hospitalisation/death and 
spirometry measures
Reproductive health indicator COPD-related hospitalisation/death FEV1 FVC FEV1/FVC
Age at menarche
  <12 years = = ↓ ↓
  12–15 years NA NA NA NA
  >15 years ↑ ↓ ↓ =
Menopause status
  No NA NA NA NA
  Yes = ↓ ↓ =
Age at natural menopause
  <47 years ↑ ↓ ↓ =
  47–49 years = = = =
  50–52 years NA NA NA NA
  >52 years = = = =
Parity, binary
  Nulliparous = ↓ ↓ ↑
  Parous NA NA NA NA
Parity, ordered categories
  0 NA NA NA NA
  1 = = ↑ ↓
  2 = ↑ ↑ ↓
  3 = ↑ ↑ ↓
  >3 ↑ ↑ ↑ ↓
PCOS/ovarian cysts
  No NA NA NA NA
  Yes ↑ = = ↑
Endometriosis
  No NA NA NA NA
  Yes = = = ↑
Oral contraception
  Never used NA NA NA NA
  Ever used ↓ ↑ ↑ =
Years of oral contraception
  0 NA NA NA NA
  1 = = = =
  2-4 = ↑ ↑ ↑
  5-9 = ↑ ↑ ↑
  10-15 ↓ ↑ ↑ =
  >15 ↓ ↑ = =
Hormone replacement therapy
  Never used NA NA NA NA
  Ever used ↑ = = ↑
Years of hormone replacement therapy
  0 NA NA NA NA
  1-2 ↑ = = ↑
Continued
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Reproductive health indicator COPD-related hospitalisation/death FEV1 FVC FEV1/FVC
  3-5 = = = =
  6-10 = = = =
  >10 = = = =
Gynaecological surgery
  No NA NA NA NA
  Hysterectomy ↑ = = ↑
  Bilateral oophorectomy = = = =
  Both ↑ = ↓ ↑
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; NA, not applicable 
where the category is the reference group; PCOS, polycystic ovary syndrome.
Table 4 Continued
an association between HRT use and greater FEV1/
FVC.14 Others have identified differences in lung func-
tion according to continuous/cyclic and combined/
oestrogen-only HRT.20 21 Based on the information from 
participants in UK Biobank, we could not stratify by HRT 
subtypes.
There are sex differences in lung anatomy and phys-
iology throughout the life course.1 2 4 During gestation, 
female foetuses have fewer bronchi, smaller lungs and 
produce surfactant earlier than male foetuses.1 Female 
neonates and children have greater lung function and 
faster lung growth than their male counterparts, and 
boys are more likely to be diagnosed with asthma during 
childhood than girls, while girls are twice as likely as 
boys to be diagnosed with asthma after puberty.1 These 
findings suggest that female sex steroids can accelerate 
lung maturation and termination of lung growth, which 
may partially explain why early menarche associates with 
lower FEV1/FVC in adulthood. During the reproductive 
years, parity and PCOS relate to an increase in circulating 
oestrogen, which has been implicated in the pathogen-
esis of inflammatory lung diseases including COPD.6 29–31 
Although OC use appears to be protective against COPD, 
some researchers have suggested that OC use attenuates 
the fluctuations in sex steroids, which correlates with fluc-
tuations in endothelial nitric oxide, a potent bronchodi-
lator.1 Additionally, exogenous hormones may not be as 
influential during reproductive years but may become 
more influential in after menopause, when endogenous 
hormone production is low.6 This is supported by our 
findings of opposing associations with COPD risk for OC 
use (lower risk) during reproductive period and HRT use 
(higher risk) after menopause.
The effect of female sex hormones on COPD and 
lung health may vary depending on the net effects on 
airway smooth muscle, inflammation and cigarette smoke 
metabolism. Oestrogens can regulate the synthesis of 
nitric oxide, a potent bronchodilator, within human 
bronchial epithelium,1 32 as well as regulate airway bron-
choconstriction in response to acetylcholine or hista-
mine.33 34 There is also evidence that progesterone may 
affect airway smooth muscle constriction, although these 
reports are limited to animal studies.35 In addition to 
regulating bronchodilation and bronchoconstriction, in 
vitro studies report that oestrogen can also modulate the 
proliferation of airway smooth muscle cells,36 37 which is a 
key feature of COPD.38 Oestrogen’s proinflammatory and 
anti-inflammatory effects have been documented in other 
female-predominant diseases39 and may also play a role in 
COPD, as chronic inflammation is another hallmark of 
the disease. Finally, oestrogen is an important regulator 
of toxic cigarette smoke metabolites through cytochrome 
P450 enzymes.1 In a mouse model of COPD, Glassberg et 
al reported that oestradiol administration after ovariec-
tomy protected against cigarette smoke-induced alve-
olar septal destruction, macrophage infiltration and 
decreased other markers of inflammation compared 
with ovariectomy without oestradiol administration.40 In 
the same mouse model, however, non-ovariectomised 
female mice also had increased small airway remodelling 
following cigarette smoke exposure when compared with 
both male mice and ovariectomised female mice.41 These 
timing-dependent, dose-dependent and cell-dependent 
signalling pathways may explain why exposure to female 
sex steroids, and oestrogen in particular, have potentially 
contradictory effects on respiratory health.
We cannot exclude a potential influence of selection 
bias, due to the low participation rate in UK Biobank. 
Women in the cohort are less likely to have ever smoked, 
have greater educational attainment, but a similar 
number of offspring, as compared with the general UK 
population (https://www. ons. gov. uk/). There is also a 
lower prevalence of self-reported COPD in UK Biobank 
(0.8%) compared with physician-diagnosed COPD in 
the general female UK population (1.68%).42 Overall, 
women participating in UK Biobank reflect a higher-ed-
ucated, more health-conscious group, with more modest 
underlying risk for COPD compared with the general 
population. We can only speculate as to how these selec-
tion factors might have influenced our associations of 
interest, but we propose that the most likely direction 
of any selection bias is towards the null (resulting in an 
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underestimation). Strengths of this study include the 
large, prospective design. However, we relied on partic-
ipants to self-report reproductive history which might 
have led to measurement error. Years of OC or HRT use 
were estimated as the difference between ages at first 
and last use. This likely resulted in overestimation of the 
duration of use, which might have attenuated our find-
ings. In addition, we were unable to distinguish between 
reversible and non-reversible airway obstruction at base-
line, as a bronchodilator was not administered before 
spirometry was conducted. Although we adjusted for 
self-reported asthma at baseline, this may have led to 
overestimation of COPD-related airway obstruction 
among participants with undiagnosed asthma. Lastly, 
we were unable to adjust for environmental tobacco 
smoke exposure as these data were not collected in UK 
Biobank. We therefore cannot exclude the possibility of 
residual bias from environmental tobacco smoke.
In conclusion, our findings indicate that several female 
reproductive health indicators across the life course 
are associated with risk of COPD hospitalisation/death 
and add to the indirect evidence suggesting that female 
reproductive hormones may have a role in COPD patho-
genesis. Further studies are necessary to understand the 
opposing associations of hysterectomy, HRT and PCOS/
ovarian cysts with COPD and objective measures of airway 
obstruction.
Author affiliations
1Bristol Medical School, Faculty of Health Sciences, University of Bristol, Bristol, UK
2Keenan Research Centre for Biomedical Science, St Michael’s Hospital, Toronto, 
Ontario, Canada
3MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK
4Department of Population Health Sciences, Bristol Medical School, University of 
Bristol, Bristol, UK
5Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway
Acknowledgements This research has been conducted using the UK Biobank 
Resource under Application Number 6326. We thank all the participants and 
researchers involved.
Contributors All authors provided substantial contributions to the design of the 
work. RT analysed the data and drafted the manuscript. MCM and AF supervised 
the study, provided further data interpretation and revised the manuscript. All 
authors approved the final version of the manuscript and agree to be accountable 
for all aspects of the work in ensuring that questions related to the accuracy or 
integrity of any part of the work are appropriately investigated and resolved.
Funding This work was supported by the UK Medical Research Council grant 
MC/UU/12013/5, which provides infrastructure funding to the MRC Integrative 
Epidemiology Unit at the University of Bristol, and grant MR/M009351/1 as a 
fellowship to AF. This work was partly supported by the Research Council of 
Norway’s Centres of Excellence scheme grant 262700.
Competing interests None declared.
Patient consent for publication Not required.
ethics approval Data collection in UK Biobank was approved by the National 
Health Service National Research Ethics Service (Ref 11/NW/0382).
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data are available in a public, open access repository.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
OrCID iD
Rosalind Tang http:// orcid. org/ 0000- 0002- 4379- 6673
reFerenCes
 1 Townsend EA, Miller VM, Prakash YS. Sex differences and sex 
steroids in lung health and disease. Endocr Rev 2012;33:1–47.
 2 Raghavan D, Jain R. Increasing awareness of sex differences in 
airway diseases. Respirology 2016;21:449–59.
 3 Raghavan D, Varkey A, Bartter T. Chronic obstructive pulmonary 
disease: the impact of gender. Curr Opin Pulm Med 2017;23:117–23.
 4 González-Arenas A, Agramonte-Hevia J. Sex steroid hormone effects 
in normal and pathologic conditions in lung physiology. Mini Rev 
Med Chem 2012;12:1055–62.
 5 Kamil F, Pinzon I, Foreman MG. Sex and race factors in early-onset 
COPD. Curr Opin Pulm Med 2013;19:140–4.
 6 Sathish V, Martin YN, Prakash YS. Sex steroid signaling: implications 
for lung diseases. Pharmacol Ther 2015;150:94–108.
 7 Fuentes N, Silveyra P. Endocrine regulation of lung disease and 
inflammation. Exp Biol Med 2018;243:1313–22.
 8 Barr RG, Wentowski CC, Grodstein F, et al. Prospective study 
of postmenopausal hormone use and newly diagnosed asthma 
and chronic obstructive pulmonary disease. Arch Intern Med 
2004;164:379–86.
 9 Gaudet MM, Carter BD, Hildebrand JS, et al. Associations of parity 
and age at first pregnancy with overall and cause-specific mortality 
in the cancer prevention study II. Fertil Steril 2017;107:179–88.
 10 Macsali F, Real FG, Plana E, et al. Early age at menarche, 
lung function, and adult asthma. Am J Respir Crit Care Med 
2011;183:8–14.
 11 Gill D, Sheehan NA, Wielscher M, et al. Age at menarche and 
lung function: a Mendelian randomization study. Eur J Epidemiol 
2017;32:701–10.
 12 Murri V, Antoniazzi F, Piazza M, et al. Lung Function in Women with 
Idiopathic Central Precocious Puberty: A Pilot Study. Horm Res 
Paediatr 2017;87:95–102.
 13 Harik-Khan R, Wise RA, Lou C, et al. The effect of gestational 
parity on FEV1 in a group of healthy volunteer women. Respir Med 
1999;93:382–8.
 14 Carlson CL, Cushman M, Enright PL, et al. Hormone replacement 
therapy is associated with higher FEV1 in elderly women. Am J 
Respir Crit Care Med 2001;163:423–8.
 15 Hayatbakhsh MR, Najman JM, O'Callaghan MJ, et al. Association 
between smoking and respiratory function before and after 
menopause. Lung 2011;189:65–71.
 16 Amaral AFS, Strachan DP, Gómez Real F, et al. Lower lung function 
associates with cessation of menstruation: UK Biobank data. Eur 
Respir J 2016;48:1288–97.
 17 Triebner K, Matulonga B, Johannessen A, et al. Menopause is 
associated with accelerated lung function decline. Am J Respir Crit 
Care Med 2017;195:1058–65.
 18 Campbell B, Davis SR, Abramson MJ, et al. Menopause, lung 
function and obstructive lung disease outcomes: a systematic 
review. Climacteric 2018;21:3–12.
 19 Memoalia J, Anjum B, Singh N, et al. Decline in pulmonary function 
tests after menopause. J Menopausal Med 2018;24:34–40.
 20 Cevrioglu AS, Fidan F, Unlu M, et al. The effects of hormone therapy 
on pulmonary function tests in postmenopausal women. Maturitas 
2004;49:221–7.
 21 Pata O, Atiş S, Utku Oz A, et al. The effects of hormone replacement 
therapy type on pulmonary functions in postmenopausal women. 
Maturitas 2003;46:213–8.
 22 Allen N, Sudlow C, Downey P, et al. Uk Biobank: current status and 
what it means for epidemiology. Health Policy Technol 2012;1:123–6.
 23 Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-Ethnic reference 
values for spirometry for the 3-95-yr age range: the global lung 
function 2012 equations. Eur Respir J 2012;40:1324–43.
 24 Schoenfeld D. The asymptotic properties of nonparametric tests for 
comparing survival distributions. Biometrika 1981;68:316–9.
 25 Global initiative for chronic obstructive lung disease (gold). Global 
strategy for the diagnosis, management, and prevention of chronic 
obstructive pulmonary disease (2019 report), 2019.
 26 Marshall A, Altman DG, Holder RL, et al. Combining estimates of 
interest in prognostic modelling studies after multiple imputation: 
current practice and guidelines. BMC Med Res Methodol 2009;9:57.
by copyright.
 o
n
 N
ovem
ber 22, 2019 at University of Bristol Library. Protected
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-030318 on 28 October 2019. Downloaded from 
14 Tang R, et al. BMJ Open 2019;9:e030318. doi:10.1136/bmjopen-2019-030318
Open access 
 27 Rossi A, Butorac-Petanjek B, Chilosi M, et al. Chronic obstructive 
pulmonary disease with mild airflow limitation: current knowledge 
and proposal for future research - a consensus document 
from six scientific societies. Int J Chron Obstruct Pulmon Dis 
2017;12:2593–610.
 28 Casanova C, Aguirre-Jaíme A, de Torres JP, et al. Longitudinal 
assessment in COPD patients: multidimensional variability and 
outcomes. Eur Respir J 2014;43:745–53.
 29 Cushman M, Legault C, Barrett-Connor E, et al. Effect of 
postmenopausal hormones on inflammation-sensitive proteins: the 
postmenopausal Estrogen/Progestin interventions (PEPI) study. 
Circulation 1999;100:717–22.
 30 Walsh BW, Paul S, Wild RA, et al. The effects of hormone 
replacement therapy and raloxifene on C-reactive protein and 
homocysteine in healthy postmenopausal women: a randomized, 
controlled trial. J Clin Endocrinol Metab 2000;85:214–8.
 31 Gol M, Akan P, Dogan E, et al. Effects of estrogen, raloxifene, and 
hormone replacement therapy on serum C-reactive protein and 
homocysteine levels. Maturitas 2006;53:252–9.
 32 Kirsch EA, Yuhanna IS, Chen Z, et al. Estrogen acutely stimulates 
endothelial nitric oxide synthase in H441 human airway epithelial 
cells. Am J Respir Cell Mol Biol 1999;20:658–66.
 33 Degano B, Mourlanette P, Valmary S, et al. Differential effects of low 
and high-dose estradiol on airway reactivity in ovariectomized rats. 
Respir Physiol Neurobiol 2003;138:265–74.
 34 Townsend EA, Thompson MA, Pabelick CM, et al. Rapid effects of 
estrogen on intracellular Ca2+ regulation in human airway smooth 
muscle. Am J Physiol Lung Cell Mol Physiol 2010;298:L521–30.
 35 Bossé Y, Ynuk B. Endocrine regulation of airway contractility is 
overlooked. J Endocrinol 2014;222:R61–73.
 36 Stamatiou R, Paraskeva E, Papagianni M, et al. The mitogenic effect 
of testosterone and 17β-estradiol on airway smooth muscle cells. 
Steroids 2011;76:400–8.
 37 Ambhore NS, Katragadda R, Raju Kalidhindi RS, et al. Estrogen 
receptor beta signaling inhibits PDGF induced human airway smooth 
muscle proliferation. Mol Cell Endocrinol 2018;476:37–47.
 38 Yan F, Gao H, Zhao H, et al. Roles of airway smooth muscle 
dysfunction in chronic obstructive pulmonary disease. J Transl Med 
2018;16:262.
 39 Straub RH. The complex role of estrogens in inflammation. Endocr 
Rev 2007;28:521–74.
 40 Glassberg MK, Catanuto P, Shahzeidi S, et al. Estrogen 
deficiency promotes cigarette smoke-induced changes in the 
extracellular matrix in the lungs of aging female mice. Transl Res 
2016;178:107–17.
 41 Tam A, Bates JHT, Churg A, et al. Sex-Related differences in 
pulmonary function following 6 months of cigarette exposure: 
implications for sexual dimorphism in mild COPD. PLoS One 
2016;11:e0164835.
 42 Simpson CR, Hippisley-Cox J, Sheikh A. Trends in the epidemiology 
of chronic obstructive pulmonary disease in England: a national 
study of 51 804 patients. Br J Gen Pract 2010;60:e277–84.
by copyright.
 o
n
 N
ovem
ber 22, 2019 at University of Bristol Library. Protected
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-030318 on 28 October 2019. Downloaded from 
